AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Pfizer's $11.63 Billion Trading Day Sees Stock Dip 0.12% Amid Eliquis Affordability Push
Generated by AI AgentAinvest Volume Radar
Thursday, Jul 17, 2025 6:54 pm ET1min read
Aime SummaryOn July 17, 2025, Pfizer's trading volume reached $11.63 billion, ranking 80th in the day's stock market. Pfizer's stock price decreased by 0.12%.
Pfizer, in collaboration with Bristol Myers Squibb, announced a significant move to enhance patient access to their blood thinner Eliquis. Starting September 8, eligible U.S. patients with a prescription can purchase Eliquis directly through the Eliquis 360 Support program. This initiative aims to make the medication more affordable by offering a 40% discount, reducing the monthly cost from $606 to $346.
This direct-to-patient program is part of a broader effort to increase affordability and accessibility for patients. Christopher Boerner, CEO of
, emphasized the commitment to improving patient access and affordability. The program will also provide copay assistance, further easing the financial burden on patients.
Ainvest Volume Radar
Hunt down the stocks with explosive trading volume.
Latest Articles
Kraft Heinz Slides 1.02% as Stock Ranks 486th in Daily Trading Volume Amid Institutional Splits Earnings Woes and Dividend Strain Weigh on Investor Confidence
Dec.05 2025
AVAV's 3.15% Slide Amid 21% Volume Drop, 475th Rank Signal Earnings Optimism Fizzles
Dec.05 2025
Align Technology Extends Three-Day Rally with 0.24 Gain Ranks 452nd in $250M Turnover as Dental Sector Outperforms Peers
Dec.05 2025
PPG's 0.36% Rise Outpaces 448th-Ranked Volume as Analysts Boost Aerospace Growth Outlook
Dec.05 2025
Akamai's FedRAMP Certification Drives 31.33% Volume Surge to 445th Rank, but Stock Dips 3.59% on Investor Caution
Dec.05 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet